CUMBERLAND PHARMACEUTICALS INC 8-K

What Happened

• Cumberland Pharmaceuticals Inc. announced that at a special shareholders meeting on June 24, 2026, shareholders approved a proposal to authorize and approve a Transaction with Apotex Inc. (via an affiliate) to integrate Cumberland’s FDA‑approved commercial products with Apotex’s U.S. branded business pursuant to an Asset Purchase Agreement dated April 22, 2026.
• Holders of 10,509,626 shares (≈70.14% of the 14,983,107 shares outstanding as of the May 12, 2026 record date) were present in person or by proxy, constituting a quorum. Votes were 10,492,455 in favor, 15,904 against, 1,267 abstentions and 4,473,481 broker non‑votes. The votes in favor represented 70.03% of outstanding shares and 99.84% of votes cast.

Key Details

• Special meeting date: June 24, 2026; Record date: May 12, 2026.
• Asset Purchase Agreement dated April 22, 2026 among Nuvo Pharmaceuticals (Ireland) DAC, Apotex Inc. and Cumberland.
• Voting totals: For 10,492,455; Against 15,904; Abstentions 1,267; Broker non‑votes 4,473,481.
• Filing signed by CFO John Hamm on June 25, 2026.

Why It Matters

• The shareholder approval clears a required corporate step for the Transaction to proceed under the April 22, 2026 Asset Purchase Agreement. If completed, Cumberland’s U.S. branded commercial products will be integrated with the Apotex affiliate’s U.S. business.
• The company notes the Transaction may be considered a sale of substantially all of Cumberland’s property and assets under Tennessee law, which is a material corporate change that could affect Cumberland’s operations, asset base and future financial profile.